We review the history of antenatal corticosteroid therapy (ACS) and present recent
experimental data to demonstrate that this, one of the pillars of perinatal care, has been …

Abstract Treatment with antenatal corticosteroids (ACS) is standard of care for women at risk
of preterm birth between 24 and 34 weeks' gestation. ACS are increasingly used for other …

Background The safety and efficacy of antenatal glucocorticoids in women in low-resource
countries who are at risk for preterm birth are uncertain. Methods We conducted a …

High‐dose betamethasone and dexamethasone are standard of care treatments for women
at risk of preterm delivery to improve neonatal respiratory and mortality outcomes. The dose …

In November, 2022, WHO published updated recommendations for antenatal corticosteroids
and tocolytic therapy1, 2 in response to new evidence about these interventions that …

BACKGROUND Although administration of antenatal corticosteroids has been shown to
decrease neonatal respiratory morbidity when given to women at risk for late preterm birth …

Minimal physiologically‐based pharmacokinetic (mPBPK) models are an alternative to full
physiologically‐based pharmacokinetic (PBPK) models as they offer reduced complexity …

Antenatal corticosteroids (ACS) successfully reduce the rates of neonatal mortality and
morbidity after preterm birth. However, this translational success story is not without …

Background Antenatal corticosteroid therapy is a standard of care for women at imminent
risk of preterm labor. However, the optimal (maximum benefit and minimal risk of side …

Background The intramuscular administration of antenatal steroids to women at risk of
preterm delivery achieves high maternal and fetal plasma steroid concentrations, which are …